MRNA Moderna, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$59.66

Period return

+7.79 (+15.02%)

Volume

4.0M

2026-07-21O $59.51 H $60.83 L $58.61 C $59.66MA5 $62.48MA20 $68.37MA60 $55.85MA120 $52.9

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 31.Highin 10 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.02%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.39%
2026. 05. 05.LowHOLD3 months ago
UBS: Neutral
US analyst rating / recommendation change.
2026. 05. 05.LowHOLD3 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2026. 05. 05.LowHOLD3 months ago
Evercore ISI Group: In-Line
US analyst rating / recommendation change.
2026. 05. 05.Low3 months ago
RBC Capital: r Perform
US analyst rating / recommendation change.
2026. 04. 02.LowHOLD4 months ago
Barclays: Equal-Weight
US analyst rating / recommendation change.
2026. 02. 23.LowBUY5 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 02. 18.LowHOLD5 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $43.2 · 20 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
HQ: Cambridge, MA, United States

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 31.	After market close (AMC)	$-2	—	—	$101.77M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-2.52	—	—	$108M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-6.37	—	—	$2.27B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-6.41	—	—	$408M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	9,086,404	$461.59M	0.39%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	7,342,096	$216.52M	0.34%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	197,844	$10.05M	0.02%	—	New position

Moderna, Inc.모더나

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 05.	UBS	—	Maintain	Neutral → Neutral	—	UBS: Neutral
2026. 05. 05.	Goldman Sachs	—	Maintain	Neutral → Neutral	—	Goldman Sachs: Neutral
2026. 05. 05.	Evercore ISI Group	—	Maintain	In-Line → In-Line	—	Evercore ISI Group: In-Line
2026. 05. 05.	RBC Capital	—	Maintain	Sector Perform → Sector Perform	—	RBC Capital: Sector Perform
2026. 04. 02.	Barclays	—	Maintain	Equal-Weight → Equal-Weight	—	Barclays: Equal-Weight
2026. 02. 23.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight